$1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the past five years, achieving an average annual return of 28.63%. An initial investment of $1,000 in COGT five years ago would now be valued at $3,577.85, highlighting the power of compounded returns. The company currently holds a market capitalization of $5.38 billion.
Cogent Biosciences Inc (COGT-Q) Stock Price and News
This article provides stock price and news for Cogent Biosciences Inc. (COGT-Q), including recent analyst ratings, announcements of new drug application submissions, and detailed clinical data presentations. The company, focused on developing precision therapies, has seen significant news regarding its drug bezuclastinib for advanced systemic mastocytosis and gastrointestinal stromal tumors.
Insiders At Cogent Biosciences Sold US$12m In Stock, Alluding To Potential Weakness
Insiders at Cogent Biosciences have sold US$12 million worth of stock over the last year, suggesting they believe the stock may be overvalued. While insider buying can be a positive signal, significant insider selling often indicates a lack of confidence in the company's future performance. This raises questions about the company's prospects despite a lack of recent large individual purchases.
Why (COGT) Price Action Is Critical for Tactical Trading
This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) focusing on its price action for tactical trading. It highlights weak near and mid-term sentiment potentially challenging a long-term positive outlook, with no clear price positioning signal and elevated downside risk. The article also outlines three AI-generated institutional trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History
Cogent Biosciences, Inc. (COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The article provides current stock information, including its price, recent performance, key financial metrics, and an overview of its product pipeline like bezuclastinib and CGT4859. It also details analyst recommendations and company financials, positioning COGT as a developer of therapies for conditions like systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Cogent Biosciences (COGT) recently received FDA acceptance for its New Drug Application for bezuclastinib, but its shares have declined over the past 30 and 90 days. Despite a 137.1% one-year return, the company's valuation appears stretched with a 11.7x Price-to-Book multiple compared to the industry average of 2.2x, given its unprofitability, lack of meaningful revenue, and shareholder dilution. Investors are paying for future pipeline potential, but the stock carries risks including continued losses and dilution.
Cogent Biosciences (COGT) Stock Price, News & Analysis
Cogent Biosciences (COGT) is a biotechnology company focused on developing precision therapies for genetically defined diseases, with its lead candidate, bezuclastinib, targeting systemic mastocytosis and GIST. The company has reported positive results from its SUMMIT, APEX, and PEAK pivotal trials and has upcoming FDA PDUFA decisions for bezuclastinib in various indications. COGT's stock has shown a 160.8% gain over the past year, and it continues to expand its pipeline beyond bezuclastinib.
Should FDA Filing Acceptance Require Action From Cogent Biosciences Stock Investors?
Cogent Biosciences received FDA acceptance for its New Drug Application (NDA) for bezuclastinib in advanced systemic mastocytosis, with a PDUFA date of June 29, 2027, and no advisory committee or review issues indicated. The NDA is based on positive APEX trial data, showing high overall response rates. Despite strong past stock performance, the company is still pre-revenue, emphasizing the importance of managing burn rate, capital access, and potential dilution as it focuses on commercial launch preparations for its lead therapy.
Cogent Bio wins third FDA review for lead asset (COGT:NASDAQ)
Cogent Biosciences (COGT) has received FDA acceptance for its marketing application for bezuclastinib, its lead candidate, for a rare form of blood cancer. This marks the third indication for which the tyrosine kinase inhibitor is under regulatory review. The company had announced this development on Tuesday.
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This acceptance is supported by positive results from the APEX pivotal trial, which showed clinically meaningful responses and durable activity in AdvSM patients. The company also has NDAs under review for NonAdvSM and GIST, with PDUFA dates in late 2026, aiming to bring bezuclastinib to market for multiple KIT-driven diseases.
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with Advanced Systemic Mastocytosis
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This NDA acceptance is based on positive results from the APEX pivotal trial, which showed clinically meaningful and durable responses in AdvSM patients. The company is also advancing NDAs for bezuclastinib in NonAdvanced Systemic Mastocytosis and GIST, with target action dates in late 2026.
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. The acceptance is based on positive results from the APEX pivotal trial, which showed significant and durable clinical responses in AdvSM patients. This marks another key regulatory step for bezuclastinib, with other NDAs already under review for NonAdvSM and GIST.
Liquidity Mapping Around (COGT) Price Events
The article provides a liquidity mapping analysis for Cogent Biosciences Inc. (NASDAQ: COGT), highlighting weak near and mid-term sentiment but a strong long-term positive outlook. It identifies key support and resistance levels and outlines three AI-generated institutional trading strategies tailored for different risk profiles, emphasizing an exceptional 85.3:1 risk-reward setup.
A drug trial found responses in 65% of patients. The FDA will review it.
Cogent Biosciences announced that the FDA has accepted its New Drug Application (NDA) for bezuclastinib to treat Advanced Systemic Mastocytosis (AdvSM), setting a PDUFA target action date of June 29, 2027. This acceptance is supported by strong data from the APEX pivotal trial, which showed a 65% overall response rate in AdvSM patients. The company also has two other bezuclastinib NDAs under FDA review for NonAdvSM and GIST, with PDUFA dates in late 2026, and has established expanded access programs for eligible U.S. patients.
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com
Cogent Biosciences director Arlene Morris sold approximately $1.69 million in company shares on August 27, 2026, through a pre-arranged trading plan, after exercising stock options on the same day. Despite the sale, analysts remain bullish on Cogent Biosciences, with price targets ranging from $45 to $62, citing positive clinical trial results for bezuclastinib and an upcoming FDA decision. The company's stock has shown impressive growth, up 189% over the past year, and it maintains strong liquid assets.
What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders
Cogent Biosciences reported widening net losses for Q2 and the half-year 2026, reaching US$96.41 million and US$193.76 million respectively, indicating increased investment in development. While these losses reinforce its pre-revenue, high-spend status, they don't change the near-term catalysts, such as upcoming FDA PDUFA dates for bezuclastinib. However, the higher cash burn raises concerns about financing conditions, potential dilution, and the company's ability to fund its pipeline, potentially affecting its valuation.
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55
H.C. Wainwright has reiterated its Buy rating on Cogent Biosciences (COGT.US), maintaining a target price of $55. This continued positive outlook suggests confidence in the company's prospects.
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?
Cogent Biosciences (COGT) recently reported wider losses in Q2 2026, with a net loss of US$96.41 million. Despite a strong 213.21% total shareholder return over the past year, recent momentum has cooled, and the stock's high price-to-book ratio of 14.1x suggests a premium valuation, justified by its peer group but carrying risks related to clinical trials and ongoing losses. The article advises investors to consider the company's future execution and potential risks.
COGT Maintained by Piper Sandler -- Price Target Raised to $55
Piper Sandler has maintained an "Overweight" rating for Cogent Biosciences (COGT) and raised its price target to $55.00, reflecting increased confidence in the company's potential, especially for its precision therapy program CGT9486. Despite this positive analyst outlook, Cogent Biosciences has a low GF Score™ of 30/100 and a high Price-to-Sales ratio of 220.78x, indicating potential overvaluation and challenges in profitability and growth, suggesting investors should proceed with caution.
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?
Cogent Biosciences (COGT) recently reported wider net losses for Q2 and H1 2026, with a net loss of US$96.41 million for the quarter and US$193.76 million for the half-year. Despite a strong 213.21% total shareholder return over the past year, its 90-day share price return of 21.38% and a recent 7-day decline suggest momentum is cooling. The company's Price-to-Book ratio of 14.1x is high compared to the broader biotech industry but aligns with its closer peers, indicating investors are weighing future pipeline execution and expected revenue growth over current financials.
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next
Cogent Biosciences (COGT) reported wider net losses for Q2 and H1 2026, leading to a 10.5% stock drop. The company's investment narrative is currently focused on cash burn and funding, with future catalysts tied to FDA reviews for bezuclastinib and launch preparedness. Investors are advised to consider the implications of sustained losses on future funding and the company's valuation.
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next
Cogent Biosciences (COGT) reported wider net losses for the second quarter and first half of 2026, leading to a 10.5% drop in its stock price. The company's increasing losses highlight ongoing cost and funding pressures, which may influence investor assessment of its research and development progress. Despite the clinical momentum of its drug, bezuclastinib, the immediate future for Cogent Biosciences is focused on cash burn and funding risks rather than earnings, with financing concerns becoming more pressing following the share price pullback.
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT
Bank of America Corp DE reduced its stake in Cogent Biosciences, Inc. by 12.6% in the first quarter, selling 150,125 shares but retaining 1,043,805 shares valued at approximately $40.18 million. Cogent Biosciences reported a quarterly loss of $0.52 per share, outperforming analyst expectations. The company currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $49.10.
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G
A group of Deerfield entities and James E. Flynn have filed an amended Schedule 13G, revealing a collective beneficial ownership of 5,006,104 shares of Cogent Biosciences (COGT) common stock, which represents 2.88% of the outstanding class. The filing indicates shared voting and dispositive power over these shares, and the group now holds 5 percent or less of this class of securities. This disclosure provides transparency on significant ownership stakes in Cogent Biosciences.
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages
Cogent Biosciences (NASDAQ:COGT) has received an average "Moderate Buy" recommendation from thirteen brokerages, with an average 12-month price target of $45.90. The company recently reported quarterly EPS of -$0.52, exceeding the consensus estimate. Institutional investors have also increased their holdings in the company.
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT
Tema ETFs LLC increased its stake in Cogent Biosciences (NASDAQ:COGT) by 36.7% in the second quarter, acquiring an additional 64,898 shares to bring its total holdings to 241,565 shares, valued at approximately $9.35 million. The biopharmaceutical company reported a quarterly loss of $0.52 per share, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating with an average price target of $45.90. Other institutional investors have also adjusted their positions in Cogent Biosciences, which currently has a market cap of $6.61 billion.
Cogent Biosciences set to report earnings ahead of FDA decisions
Cogent Biosciences is preparing to release its second-quarter earnings report, with investor attention focused on the company's commercial readiness as it transitions from a clinical-stage to a marketed-drug business. Analysts anticipate a loss of $0.555 per share for the quarter, and the company is advancing regulatory filings for its lead drug candidate, bezuclastinib, for which the FDA has set a target action date of December 30, 2026, for one of its applications. Key areas of interest include updates on commercial launch preparations, regulatory progress, and the company's cash burn trajectory as it builds out its commercial infrastructure.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences announced its second-quarter 2026 financial results and recent business highlights. The company is on track for potential FDA approval of its drug bezuclastinib for GIST and NonAdvSM later this year, having submitted three New Drug Applications. Cogent also reported a strong pro forma cash balance of $865.9 million, sufficient to fund operations into late 2028, and detailed progress in its clinical trials and commercial team development.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences reported strong second-quarter 2026 financial results and significant business highlights, including progress toward potential FDA approvals for bezuclastinib for GIST and NonAdvSM later this year. The company also announced the successful onboarding of a cross-functional customer-facing team and a robust pro forma cash balance of $865.9 million, expected to fund operations into late 2028. Key clinical data from the PEAK and APEX trials were presented, demonstrating substantial benefits of bezuclastinib in treating GIST and Advanced Systemic Mastocytosis.
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program
Cogent Biosciences (COGT) has filed a prospectus supplement for an at-the-market (ATM) stock program, allowing it to offer and sell up to $400 million of its common stock. This program uses an existing automatic shelf registration statement and permits sales through Guggenheim Securities, LLC. The filing establishes capacity for future stock sales but does not represent an immediate issuance or receipt of proceeds.
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines
Cogent Biosciences (NASDAQ: COGT) has provided updates on its financial runway and the FDA timelines for its drug bezuclastinib. The company reported a net loss of $96.4 million for Q2 2026, widening from the previous year, but has $792.3 million in cash, cash equivalents, and marketable securities, projected to fund operations into late 2028. Bezuclastinib has three New Drug Applications under FDA review, with PDUFA dates in November and December 2026 for GIST and systemic mastocytosis, respectively, and management anticipates a potential commercial launch in late 2026.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences reported strong second-quarter 2026 financial results and significant progress toward the potential FDA approval of bezuclastinib for GIST and NonAdvSM later this year. The company announced the successful onboarding of its customer-facing team and a robust cash balance of $865.9 million, sufficient to fund operations into late 2028. Key milestones include NDA submissions, positive clinical trial data presentations for bezuclastinib, and advancements in its broader pipeline of precision therapies.
Press Release: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences has announced its recent business highlights and financial results for the second quarter of 2026. The report will likely cover advancements in their drug development pipeline, particularly for rare diseases, and provide an overview of their financial performance, including revenue and expenses. This release is crucial for investors and stakeholders to understand the company's progress and financial health.
Cogent Biosciences set to report earnings ahead of FDA decisions
Cogent Biosciences is scheduled to report second-quarter earnings, with investors keenly watching for updates on its commercial launch preparations for bezuclastinib, its lead drug candidate, ahead of potential FDA approvals later this year. The company is transitioning from a clinical-stage to a marketed-drug business and analysts expect a wider loss of $0.555 per share. Regulatory progress, cash burn, and launch strategies will be key areas of focus as the stock has seen a significant surge over the past year.
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
Cogent Biosciences announced its second-quarter 2026 financial results and provided key business highlights. The company is on track for potential FDA approval of bezuclastinib for GIST and Non-AdvSM later this year, with an AdvSM New Drug Application already submitted. Cogent also reported a strong cash balance of $865.9 million, sufficient to fund operations into late 2028, and detailed the successful onboarding of its commercial and medical teams.
Cogent Biosciences Q2 loss widens as bezuclastinib FDA deadlines approach
Cogent Biosciences (COGT) reported a widened net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, driven by increased R&D and G&A expenses. The company has sufficient cash runway into late 2028 and is approaching key FDA PDUFA dates for bezuclastinib in GIST and NonAdvSM in November and December 2026, respectively. Insider trading activity shows significant sales, while institutional investors present a mixed picture of additions and reductions in COGT holdings.
Cogent Biosciences (COGT) widens Q2 loss but nears FDA decisions on bezuclastinib
Cogent Biosciences reported a wider net loss of $96.4 million in Q2 2026, up from $73.5 million in Q2 2025, primarily due to increased R&D and G&A expenses. Despite this, the company is advancing towards potential FDA approvals for bezuclastinib in GIST (November 30, 2026) and Advanced Systemic Mastocytosis (December 30, 2026), supported by positive pivotal trial data. Cogent Biosciences also highlighted a strong cash position of $865.9 million (pro forma), expected to fund operations into late 2028, including potential product launches.
Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec.
Cogent Biosciences reported its Q2 2026 financial results, highlighting significant progress for its drug bezuclastinib with FDA New Drug Applications submitted for GIST and systemic mastocytosis. The company anticipates FDA decisions for GIST by November 30, 2026, and for NonAdvSM by December 30, 2026. Despite an increase in operating expenses and net loss, Cogent maintains a strong cash position of $865.9 million (pro forma) which is expected to fund operations into late 2028, supporting potential launches and pipeline advancement.
Cogent Biosciences, Inc. $COGT Shares Sold by Hennion & Walsh Asset Management Inc.
Hennion & Walsh Asset Management Inc. significantly reduced its stake in Cogent Biosciences (NASDAQ:COGT) by 59.6% in the second quarter, selling 194,697 shares but retaining 131,775 shares valued at approximately $5.1 million. Despite this sale, analyst sentiment for Cogent Biosciences remains positive with a "Moderate Buy" consensus and an average price target of $45.90. The company's stock opened at $42.39, near its 52-week high, and has a market capitalization of $7.24 billion.
Assenagon Asset Management S.A. Increases Stock Position in Cogent Biosciences, Inc. $COGT
Assenagon Asset Management S.A. significantly increased its stake in Cogent Biosciences, Inc. (NASDAQ:COGT) by 387.7% in the second quarter, now holding 1.44 million shares valued at $55.8 million. Other major institutional investors like Deerfield Management, RTW Investments, Vanguard, and T. Rowe Price also expanded their positions in the company. Cogent Biosciences shares are trading near their 12-month high, with analysts maintaining a "Moderate Buy" rating and an average price target of $45.90, despite the company being unprofitable.
If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Cogent Biosciences (NASDAQ: COGT) has significantly outperformed the market over the past five years, with an annualized return of 40.76%. An initial investment of $100 in COGT stock five years ago would now be worth $584.69. This article highlights the power of compounded returns in investment growth over time.
Loss-Making Cogent Biosciences, Inc. (NASDAQ:COGT) Expected To Breakeven In The Medium-Term
This article analyzes Cogent Biosciences, Inc.'s financial performance and future prospects, focusing on its path to breakeven. Analysts project the company to reach profitability within two years, with significant revenue growth expected in the coming years. The piece also delves into the risks and opportunities associated with investing in high-growth, loss-making companies like Cogent.
Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts
Cogent Biosciences (COGT) shares rose 10.2% due to renewed investor optimism regarding its drug bezuclastinib and a busy regulatory schedule. The company recently submitted its third NDA for bezuclastinib in six months, with decisions for other applications expected later in 2026. Cogent is also preparing for dual commercial launches and reported strong cash reserves, easing near-term financing concerns.
Behavioral Patterns of COGT and Institutional Flows
This article analyzes Cogent Biosciences Inc. (NASDAQ: COGT) focusing on its behavioral patterns and institutional flows. Key findings indicate a near-term neutral sentiment amidst mid and long-term strength, with a notable 83.7:1 risk-reward setup. The analysis provides specific institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for various horizons.
Seven Fleet Capital Management LP Sells 64,700 Shares of Cogent Biosciences, Inc. $COGT
Seven Fleet Capital Management LP significantly reduced its stake in Cogent Biosciences by selling 64,700 shares, retaining 149,399 shares valued at approximately $5.75 million. This divestment occurred while other institutional investors like Royal Bank of Canada and California State Teachers Retirement System increased their holdings. Cogent Biosciences reported quarterly EPS of negative $0.53, aligning with estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $45.90.
Vanguard Capital Management discloses 5.08% Cogent Biosciences (COGT) ownership in 13G filing
Vanguard Capital Management LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.08% in Cogent Biosciences Inc (COGT), amounting to 8,691,589 shares. The filing indicates that Vanguard holds sole voting power over 1,279,259 shares and sole dispositive power over all 8,691,589 shares, with no shared voting or dispositive power. This ownership reflects holdings across various Vanguard funds and managed accounts, but no other individual entity holds more than a 5% interest.
COGT|Cogent Biosciences Inc|Price:39.585|Chg%:-1.085
This article provides a comprehensive stock analysis of Cogent Biosciences Inc (COGT) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and high institutional ownership. The valuation is considered fairly valued, and analysts have issued a "Buy" rating with a target price indicating significant upside.
Cogent Biosciences Market Sentiment
This article analyzes market sentiment for Cogent Biosciences (COGT) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" analyst consensus with 16 analysts, a 9.6% rising short float, and a bullish options flow with a 0.27 Put/Call ratio. The piece also details recent analyst actions, including price target changes and ratings.
Cogent Biosciences Inc (COGT) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Cogent Biosciences Inc (COGT) by TradingKey, focusing on its profitability and balance sheet. The company has a current financial score of 6.80, ranking 205 out of 384 in its industry, indicating robust financial status but low operational efficiency. Key financial metrics for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Cogent Biosciences Inc (COGT) Institutional Confidence
Cogent Biosciences Inc (COGT) has achieved an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion recently increased by 14.34% quarter-over-quarter, reaching 102.81%. Steven Cohen is the largest institutional shareholder, holding 6.61 million shares, which represents 3.47% of shares outstanding after a 320.25% increase in his holdings.
